PAM
RGLS

Panagora Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Panagora Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-78
Closed -$1K – 2604
2019
Q2 		$1K Buy
+78
New +$898 ﹤0.01% 2568
2019
Q1 		– Sell
-2,291
Closed -$21K – 2559
2018
Q4 		$21K Buy
2,291
+1,232
+116% +$20.4K ﹤0.01% 2206
2018
Q3 		$25K Buy
1,059
+356
+51% +$11.7K ﹤0.01% 2177
2018
Q2 		$56K Buy
703
+44
+7% +$3.64K ﹤0.01% 2012
2018
Q1 		$57K Hold
659
– – ﹤0.01% 1997
2017
Q4 		$82K Buy
+659
New +$83.4K ﹤0.01% 1940
2017
Q3 		– Sell
-16
Closed -$2K – 2466
2017
Q2 		$2K Hold
16
– – ﹤0.01% 2551
2017
Q1 		$3K Buy
+16
New +$3.04K ﹤0.01% 2322
2016
Q1 		– Sell
-44
Closed -$46K – 2332
2015
Q4 		$46K Sell
44
-15
-25% -$15K ﹤0.01% 2000
2015
Q3 		$46K Buy
+59
New +$60.6K ﹤0.01% 2012
2013
Q3 		– Sell
-181
Closed -$213K – 2352
2013
Q2 		$213K Buy
+181
New +$172K ﹤0.01% 1612

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Panagora Asset Management's RGLS Position: Q3 2019 in Review

Panagora Asset Management sold out of Regulus Therapeutics (RGLS) in Q3 2019, closing a stake of 78 shares — an estimated $1K sold.

Panagora Asset Management first reported a position in RGLS in Q2 2013 and held it in 11 quarters. The position peaked at $213K in Q2 2013. 28 funds tracked by Wall St. Rank hold RGLS as of Q3 2019.

  • Panagora Asset Management reported no remaining Regulus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Panagora Asset Management sold 78 Regulus Therapeutics shares in Q3 2019, an estimated $1K.
  • Panagora Asset Management first reported a position in Regulus Therapeutics in Q2 2013 and held it in 11 quarters.
  • Panagora Asset Management's Regulus Therapeutics position peaked at $213K in Q2 2013.
  • 28 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.